Compare ALKT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKT | NBTX |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2021 | 2018 |
| Metric | ALKT | NBTX |
|---|---|---|
| Price | $18.79 | $39.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $28.57 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 2.1M | 66.2K |
| Earning Date | 04-29-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,159,000.00 | N/A |
| Revenue This Year | $21.85 | $58.17 |
| Revenue Next Year | $16.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.68 | N/A |
| 52 Week Low | $13.98 | $4.79 |
| 52 Week High | $30.88 | $57.14 |
| Indicator | ALKT | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.59 | 57.25 |
| Support Level | $15.16 | $38.89 |
| Resistance Level | $19.23 | $41.89 |
| Average True Range (ATR) | 0.76 | 2.55 |
| MACD | 0.41 | 0.45 |
| Stochastic Oscillator | 91.35 | 96.34 |
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.